Related Experiment Video
Updated: May 26, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma
Kenya Yamanaka1, Etsuro Hatano, Koji Kitamura
1Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Background:
There is no standard therapy for patients with transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). This study examined whether evaluating the tumor effect (TE) at 1 week after TACE was useful for predicting refractoriness to TACE.
Methods:
We performed a historical cohort study involving 54 patients and 119 tumors. TE was evaluated at 1 week and 3 months after TACE, and an overall evaluation was also performed at 3 months based on the response evaluation criteria in cancer of the liver.
Results:
Among 45 tumors evaluated as TE2 at 1 week, 43 tumors (95.6%) were classified as TE1 or TE2 at 3 months. Of the 24 patients whose tumors were categorized as TE2 at 1 week, none achieved a complete or partial response.
Conclusions:
Evaluating the TE at 1 week after TACE is useful for the early diagnosis of TACE-refractory HCC and allows alternative treatment options, such as sorafenib, to be employed before the disease progresses.
More Related Videos
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024